Jun 17, 2020
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit
May 31, 2020
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
May 14, 2020
Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome
Apr 30, 2020
China National Medical Products Administration Approves DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Apr 22, 2020
Fibrinogen Market Growth Analysis to 2023 - Featuring Key Players: Shanghai XinXing Medical, CSL Behring, Greencross, Johnson & Johnson, Baxter, LFB Group, & ProFibrix BV | Radiant Insights, Inc.
Apr 17, 2020
GC Pharma lights up to celebrate 'World Hemophilia Day'
Apr 17, 2020
World Hemophilia Day 2020
Apr 06, 2020
HEMA Biologics(TM) Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Apr 01, 2020
FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors
Mar 18, 2020
Cellphire Begins Phase 2 Trial of Thrombosomes® in Bleeding Thrombocytopenic Patients
Mar 16, 2020
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Mar 05, 2020
New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Mar 02, 2020
Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Mar 02, 2020
Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Mar 02, 2020
Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Feb 26, 2020
Hemophilia A - Forecasts for Seven Major Markets Covering the United States, EU5 and Japan
Feb 24, 2020
MedaRed Announces Name Change to Therini Bio
Feb 20, 2020
EmCyte Announces the Acquisition of the Centrepid Platelet Concentrator
Feb 04, 2020
Haemostasis Valves Market Promises a Buoyant Path to Growth with 4.5% CAGR During 2019-2027 Amidst Rising Cases of Cancer: Transparency Market Research
Jan 02, 2020
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A